Klaartje Kok

5PUBLICATIONS
46CO-AUTHORS
Epidemiological methodsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 10, 2026
Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group.

|Jul 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.

Nicholas A Kennedy, Malik Janjua, Neil Chanchlani

|Sep 02, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.

Neil Chanchlani, Simeng Lin, Desmond Chee

|Apr 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.

Nicholas A Kennedy, Simeng Lin, James R Goodhand

|Mar 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.

Nicholas A Kennedy, James R Goodhand, Claire Bewshea

Pageof 1

Frequent Collaborators

4 joint publications

Nicholas A Kennedy

4 joint publications

James R Goodhand

4 joint publications

Claire Bewshea

4 joint publications

Simeng Lin